Keywords: Neoplasms, Radiopharmaceuticals, Theranostics, 1 Fluoro 3 (2 Nitro 1 Imidazolyl) 2 Propanol F 18, Antineoplastic Agent, Cetuximab, Cetuximab Macrogol Pentetate Indium In 111, Cisplatin, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Kinase Inhibitor, Fluorodeoxyglucose F 18, Fluoroerythronitroimidazole F 18, Fluorothymidine F 18, Gemtuzumab Ozogamicin, Glycoprotein P Inhibitor, Ibritumomab Tiuxetan, Imatinib, Methoxy Isobutyl Isonitrile Technetium Tc 99m, Methylthiosemicarbazone Cu 62, Monoclonal Antibody, Monoclonal Antibody 528 Pentetate Indium In 111, Protein Tyrosine Kinase Inhibitor, Radiopharmaceutical Agent, Scatter Factor Receptor, Sorafenib, Sunitinib, Tositumomab I 131, Trastuzumab, Tumor Antigen, Unclassified Drug, Unindexed Drug, Upenazime Tc 99m, Yttrium 86, Acute Granulocytic Leukemia, Cancer, Cancer Chemotherapy, Cancer Diagnosis, Cancer Growth, Cancer Theranostics, Clinical Trial, Diagnostic Accuracy, Drug Distribution, Drug Response, Drug Targeting, Drug Treatment Failure, Human, Hypoxia, Isotope Labeling, Lung Non Small Cell Cancer, Molecular Imaging, Multidrug Resistance, Nonhodgkin Lymphoma, Nonhuman, Nuclear Medicine, Positron Emission Tomography, Protein Expression, Radioimmunotherapy, Review, Sensitivity And Specificity, Single Photon Emission Computer Tomography, Animals, Diagnostic Imaging, Drug Delivery Systems, Drug Design, Forecasting, Molecular Probe Techniques, Diagnostic Imaging Trends
, Drug Delivery Systems Trends
, Isotope Labeling Methods
, Molecular Probe Techniques Trends
, Neoplasms Diagnostic Imaging Radiotherapy
, Nuclear Medicine Trends
, Radionuclide Imaging
, Radiopharmaceuticals Therapeutic Use,
Affiliations: *** IBB - CNR ***
Department of Biomorphological and Functional Sciences, University of Naples Federico II, Edificio 10, Via S. Pansini 5, 80131 Naples, Italy
Institute of Biostructures and Bioimages, National Council of Research (CNR), Naples, Italy
References: Hayes, D.F., Prognostic and predictive factors revisited (2005) Breast, 14, pp. 493-49
Colozza, M., Cardoso, F., Sotiriou, C., Larsimont, D., Piccart, M.J., Bringing molecular prognosis and prediction to the clinic (2005) Clin Breast Cancer, 6, pp. 61-76
Chang, J.C., Wooten, E.C., Tsimelzon, A., Hilsenbeck, S.G., Gutierrez, M.C., Tham, Y.L., Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients (2005) J Clin Oncol, 23, pp. 1169-1177
Gianni, L., Zambetti, M., Clark, K., Baker, J., Cronin, M., Wu, J., Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer (2005) J Clin Oncol, 23, pp. 7265-7277
Jeffrey, S.S., Lonning, P.E., Hillner, B.E., Genomics-based prognosis and therapeutic prediction in breast cancer (2005) J Natl Compr Canc Netw, 3, pp. 291-300
Robbins, R.J., Schlumberger, M.J., The evolving role of (131)I for the treatment of differentiated thyroid carcinoma (2005) J Nucl Med, 46 (SUPPL. 1), pp. 28S-37S
Reubi, J.C., Macke, H.R., Krenning, E.P., Candidates for peptide receptor radiotherapy today and in the future (2005) J Nucl Med, 46 (SUPPL. 1), pp. 67S-75S
Corsten, M.F., Hofstra, L., Narula, J., Reutelingsperger, C.P., Counting heads in the war against cancer: Defining the role of annexin A5 imaging in cancer treatment and surveillance (2006) Cancer Res, 66, pp. 1255-1260
Haubner, R., Wester, H.J., Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies (2004) Curr Pharm Des, 10, pp. 1439-1455
Weber, W.A., Wieder, H., Monitoring chemotherapy and radiotherapy of solid tumors (2006) Eur J Nucl Med Mol Imaging, 33 (SUPPL. 13), pp. 27-37
Reilly, R.M., Kiarash, R., Sandhu, J., Lee, Y.W., Cameron, R.G., Hendler, A., A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer (2000) J Nucl Med, 41, pp. 903-911
Wen, X., Wu, Q.P., Ke, S., Ellis, L., Charnsangavej, C., Delpassand, A.S., Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225 (2001) J Nucl Med, 42, pp. 1530-1537
Yang, W., Barth, R.F., Wu, G., Ciesielski, M.J., Fenstermaker, R.A., Moffat, B.A., Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4 (2005) Clin Cancer Res, 11, pp. 341-350
Takasu, S., Takahashi, T., Okamoto, S., Oriuchi, N., Nakayashiki, N., Okamoto, K., Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor (2003) J Neurooncol, 63, pp. 247-256
Ramos-Suzarte, M., Rodriguez, N., Oliva, J.P., Iznaga-Escobar, N., Perera, A., Morales, A., 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy (1999) J Nucl Med, 40, pp. 768-775
Schillaci, O., Danieli, R., Picardi, V., Bagrii, O., Di Loreto, M., Scopinaro, F., Immunoscintigraphy with a technetium-99m labelled anti-epithelial growth factor receptor antibody in patients with non-small cell lung cancer (2001) Anticancer Res, 21, pp. 3571-3574
Perk, L.F., Visser, G.W., Vosjan, M.J., Stigter-van Walsum, M., Tijink, B.M., Leemans, C.R., (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab (2005) J Nucl Med, 46, pp. 1898-1906
Velikyan, I., Sundberg, A.L., Lindhe, O., Hoglund, A.U., Eriksson, O., Werner, E., Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors (2005) J Nucl Med, 46, pp. 1881-1888
Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., McGuire, W.L., Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene (1987) Science, 235, pp. 177-182
Goldenberg, A., Masui, H., Divgi, C., Kamrath, H., Pentlow, K., Mendelsohn, J., Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody (1989) J Natl Cancer Inst, 81, pp. 1616-1625
Saga, T., Endo, K., Akiyama, T., Sakahara, H., Koizumi, M., Watanabe, Y., Scintigraphic detection of overexpressed c-erbB-2 protoon-cogene products by a class-switched murine anti-c-erbB-2 protein monoclonal antibody (1991) Cancer Res, 51, pp. 990-994
De Santes, K., Slamon, D., Anderson, S.K., Shepard, M., Fendly, B., Maneval, D., Radiolabeled antibody targeting of the HER-2/neu oncoprotein (1992) Cancer Res, 52, pp. 1916-1923
Rusckowski, M., Qu, T., Chang, F., Hnatowich, D.J., Technetium-99m labeled epidermal growth factor-tumor imaging in mice (1997) J Pept Res, 50, pp. 393-401
Zalutsky, M.R., Xu, F.J., Yu, Y., Foulon, C.F., Zhao, X.G., Slade, S.K., Radioiodinated antibody targeting of the HER-2/neu oncoprotein: Effects of labeling method on cellular processing and tissue distribution (1999) Nucl Med Biol, 26, pp. 781-790
Tsai, S.W., Sun, Y., William, L.E., Raubitschek, A.A., Wu, A.M., Shively, J.E., Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5 (2000) Bioconjug Chem, 11, pp. 327-334
Garmestani, K., Milenic, D.E., Plascjak, P.S., Brechbiel, M.W., A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin (2002) Nucl Med Biol, 29, pp. 599-606
Palm, S., Enmon Jr, R.M., Matei, C., Kolbert, K.S., Xu, S., Zanzonico, P.B., Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: Correlative microPET and MRI (2003) J Nucl Med, 44, pp. 1148-1155
Kobayashi, H., Shirakawa, K., Kawamoto, S., Saga, T., Sato, N., Hiraga, A., Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)(256) (2002) Cancer Res, 62, pp. 860-866
Tang, Y., Wang, J., Scollard, D.A., Mondal, H., Holloway, C., Kahn, H.J., Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments (2005) Nucl Med Biol, 32, pp. 51-58
Nordberg, E., Steffen, A.C., Persson, M., Sundberg, A.L., Carlsson, J., Glimelius, B., Cellular uptake of radioiodine delivered by trastuzumab can be modified by the addition of epidermal growth factor (2005) Eur J Nucl Med Mol Imaging, 32, pp. 771-777
Orlova, A., Nilsson, F.Y., Wikman, M., Widstrom, C., Stahl, S., Carlsson, J., Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors (2006) J Nucl Med, 47, pp. 512-519
Perik, P.J., Lub-De Hooge, M.N., Gietema, J.A., van der Graaf, W.T., de Korte, M.A., Jonkman, S., Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer (2006) J Clin Oncol, 24, pp. 2276-2282
Robinson, M.K., Doss, M., Shaller, C., Narayanan, D., Marks, J.D., Adler, L.P., Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody (2005) Cancer Res, 65, pp. 1471-1478
Olafsen, T., Kenanova, V.E., Sundaresan, G., Anderson, A.L., Crow, D., Yazaki, P., Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging (2005) Cancer Res, 65, pp. 5907-5916
Smith-Jones, P.M., Solit, D.B., Akhurst, T., Afroze, F., Rosen, N., Larson, S.M., Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors (2004) Nat Biotechnol, 22, pp. 701-706
Hay, R.V., Cao, B., Skinner, R.S., Su, Y., Zhao, P., Gustafson, M.F., Nuclear imaging of Met-expressing human and canine cancer xenografts with radiolabeled monoclonal antibodies (MetSeek) (2005) Clin Cancer Res, 11, pp. 7064s-77069. , s
Bonasera, T.A., Ortu, G., Rozen, Y., Krais, R., Freedman, N.M., Chisin, R., Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase (2001) Nucl Med Biol, 28, pp. 359-374
Ortu, G., Ben-David, I., Rozen, Y., Freedman, N.M., Chisin, R., Levitzki, A., Labeled EGFr-TK irreversible inhibitor (ML03): In vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug (2002) Int J Cancer, 101, pp. 360-370
Mishani, E., Abourbeh, G., Rozen, Y., Jacobson, O., Laky, D., Ben David, I., Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: Potential PET bioprobes for molecular imaging of EGFR-positive tumors (2004) Nucl Med Biol, 31, pp. 469-476
Calvo, E., Baselga, J., Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors (2006) J Clin Oncol, 24, pp. 2158-2163
Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib (2004) N Engl J Med, 350, pp. 2129-2139
Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy (2004) Science, 304, pp. 1497-1500
Johnson, B.E., Janne, P.A., Epidermal growth factor receptor mutations in patients with non-small cell lung cancer (2005) Cancer Res, 65, pp. 7525-7529
Ackermann, U., Tochon-Danguy, H.J., Nerrie, M., Nice, E.C., Sachinidis, J., Scott, A.M., Synthesis, 11C labeling and biological properties of derivatives of the tyrphostin AG957 (2005) Nucl Med Biol, 32, pp. 323-328
Veach, D.R., Namavari, M., Beresten, T., Balatoni, J., Minchenko, M., Djaballah, H., Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors (2005) Nucl Med Biol, 32, pp. 313-321
Adams, G.P., Weiner, L.M., Monoclonal antibody therapy of cancer (2005) Nat Biotechnol, 23, pp. 1147-1157
Spies, S.M., Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevahn) (2004) Semin Nucl Med, 34, pp. 10-13
Conti, P.S., Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin): The role of the nuclear medicine physician (2004) Semin Nucl Med, 34, pp. 2-3
Conti, P.S., White, C., Pieslor, P., Molina, A., Aussie, J., Foster, P., The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: Results from a Zevalin Imaging Registry (2005) J Nucl Med, 46, pp. 1812-1818
DeNardo, G.L., Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs) (2005) Semin Nucl Med, 35, pp. 202-211
Lewington, V., Development of 131I-tositumomab (2005) Semin Oncol, 32, pp. S50-S56
Wu, A.M., Senter, P.D., Arming antibodies: Prospects and challenges for immunoconjugates (2005) Nat Biotechnol, 23, pp. 1137-1146
Sundaresan, G., Yazaki, P.J., Shively, J.E., Finn, R.D., Larson, S.M., Raubitschek, A., 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice (2003) J Nucl Med, 44, pp. 1962-1969
Kenanova, V., Olafsen, T., Crow, D.M., Sundaresan, G., Subbarayan, M., Carter, N.H., Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments (2005) Cancer Res, 65, pp. 622-631
Begent, R.H., Verhaar, M.J., Chester, K.A., Casey, J.L., Green, A.J., Napier, M., Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library (1996) Nat Med, 2, pp. 979-984
Larson, S.M., El-Shirbiny, A.M., Divgi, C.R., Sgouros, G., Finn, R.D., Tschmelitsch, J., Single chain antigen binding protein (sFv CC49): First human studies in colorectal carcinoma metastatic to liver (1997) Cancer, 80, pp. 2458-2468
Wong, J.Y., Chu, D.Z., Williams, L.E., Yamauchi, D.M., Ikle, N., Kwok, C.S., Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer (2004) Clin Cancer Res, 10, pp. 5014-5021
Grunberg, J., Novak-Hofer, I., Honer, M., Zimmermann, K., Knogler, K., Blauenstein, P., In vivo evaluation of 177Lu- and 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors (2005) Clin Cancer Res, 11, pp. 5112-5120
Shields, A.F., Grierson, J.R., Dohmen, B.M., Machulla, H.J., Stayanoff, J.C., Lawhorn-Crews, J.M., Imaging proliferation in vivo with [F-18]FLT and positron emission tomography (1998) Nat Med, 4, pp. 1334-1336
Been, L.B., Suurmeijer, A.J., Cobben, D.C., Jager, P.L., Hoekstra, H.J., Elsinga, P.H., 18F]FLT-PET in oncology: Current status and opportunities (2004) Eur J Nucl Med Mol Imaging, 31, pp. 1659-1672
Buck, A.K., Schirrmeister, H., Hetzel, M., Von Der Heide, M., Halter, G., Glatting, G., 3-deoxy-3-[(18)F]fluorothynidine-positron emission tomography for noninvasive assessment of proliteration in pulmonary nodules (2002) Cancer Res, 62, pp. 3331-3334
Vesselle, H., Grierson, J., Muzi, M., Pugsley, J.M., Schmidt, R.A., Rabinowitz, P., In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: Correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors (2002) Clin Cancer Res, 8, pp. 3315-3323
Dittmann, H., Dohmen, B.M., Paulsen, F., Eichhorn, K., Eschmann, S.M., Horger, M., 18F]FLT PET for diagnosis and staging of thoracic tumours (2003) Eur J Nucl Med Mol Imaging, 30, pp. 1407-1412
Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G et al. M. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003
44:1426-31Muzi, M., Vesselle, H., Grierson, J.R., Mankoff, D.A., Schmidt, R.A., Peterson, L., Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: Validation studies in patients with lung cancer (2005) J Nucl Med, 46, pp. 274-282
Buck, A.K., Hetzel, M., Schirrmeister, H., Halter, G., Moller, P., Kratochwil, C., Clinical relevance of imaging proliferative activity in lung nodules (2005) Eur J Nucl Med Mol Imaging, 32, pp. 525-533
Yap, C.S., Czernin, J., Fishbein, M.C., Cameron, R.B., Schiepers, C., Phelps, M.E., Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography (2006) Chest, 129, pp. 393-401
van Westreenen, H.L., Cobben, D.C., Jager, P.L., van Dullemen, H.M., Wesseling, J., Elsinga, P.H., Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer (2005) J Nucl Med, 46, pp. 400-404
Francis, D.L., Visvikis, D., Costa, D.C., Arulampalam, T.H., Townsend, C., Ludira, S.K., Potential impact of [18F]3′-deoxy-3′-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal. cancer (2003) Eur J Nucl Med Mol Imaging, 30, pp. 988-994
Visvikis, D., Francis, D., Mulligan, R., Costa, D.C., Croasdale, I., Luthra, S.K., Comparison of methodologies for the in vivo assessment of 18FLT utilisation in colorectal. cancer (2004) Eur J Nucl Med Mol Imaging, 31, pp. 169-178
Wagner, M., Seitz, U., Buck, A., Neumaier, B., Schultheiss, S., Bangerter, M., 3′-[18F]fluoro-3′-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease (2003) Cancer Res, 63, pp. 2681-2687
Jacobs, A.H., Thomas, A., Kracht, L.W., Li, H., Dittmar, C., Garhp, G., 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors (2005) J Nucl Med, 46, pp. 1948-1958
Choi, S.J., Kim, J.S., Kim, J.H., Oh, S.J., Lee, J.G., Kim, C.J., 18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors (2005) Eur J Nucl Med Mol Imaging, 32, pp. 653-659
Chen, W., Cloughesy, T., Kamdar, N., Satyamurthy, N., Bergsneider, M., Liau, L., Imaging proliferation in brain tumors with 18F-FLT PET: Comparison with 18F-FDG (2005) J Nucl Med, 46, pp. 945-952
Smyczek-Gargya, B., Fersis, N., Dittmann, H., Vogel, U., Reischl, G., Machulla, H.J., PET with [18F]fluorothymidine for imaging of primary breast cancer: A pilot study (2004) Eur J Nucl Med Mol Imaging, 31, pp. 720-724
Kenny, L.M., Vigushin, D.M., Al-Nahhas, A., Osman, S., Luthra, S.K., Shousha, S., Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: Evaluation of analytical methods (2005) Cancer Res, 65, pp. 10104-10112
Leyton, J., Latigo, J.R., Perumal, M., Dhaliwal, H., He, Q., Aboagye, E.O., Early detection of tumor response to chemotherapy by 3′-deoxy-3′[18F]fluorothymidine positron emission tomography: The effect of cisplatin on a fibrosarcoma tumor model in vivo (2005) Cancer Res, 65, pp. 4202-4210
Yang, Y.J., Ryu, J.S., Kim, S.Y., Oh, S.J., Im, K.C., Lee, H., Use of 3′-deoxy-3′-[(18)F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors (2006) Eur J Nucl Med Mol Imaging, 33, pp. 412-419
Waldherr, C., Mellinghoff, I.K., Tran, C., Halpern, B.S., Rozengurt, N., Safaei, A., Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F-fluorothymidine PET (2005) J Nucl Med, 46, pp. 114-120
Szakacs, G., Paterson, J.K., Ludwig, J.A., Booth-Genthe, C., Gottesman, M.M., Targeting multidrug resistance in cancer (2006) Nat Rev Drug Discov, 5, pp. 219-234
Gottesman, M.M., Fojo, T., Bates, S.E., Multidrug resistance in cancer: Role of ATP-dependent transporters (2002) Nat Rev Cancer, 2, pp. 48-58
Leonard, G.D., Fojo, T., Bates, S.E., The role of ABC transporters in clinical practice (2003) Oncologist, 8, pp. 411-424
Trock, B.J., Leonessa, F., Clarke, R., Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance (1997) J Natl Cancer Inst, 89, pp. 917-931
Sharma, V., Radiopharmaceuticals for assessment of multidrug resistance P-glycoprotein-mediated drug transport activity (2004) Bioconjug Chem, 15, pp. 1464-1474
Vaalburg, W., Hendrikse, N.H., Elsinga, P.H., Bart, J., van Waarde, A., P-glycoprotein activity and biological response (2005) Toxicol Appl Pharmacol, 207, pp. 257-260
Vaidyanathan, G., Zalutsky, M.R., Imaging drug resistance with radio-labeled molecules (2004) Curr Pharm Des, 10, pp. 2965-2979
Vecchio, S.D., Ciarmiello, A., Potena, M.I., Carriero, M.V., Mainolfi, C., Botti, G., In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients (1997) Eur J Nucl Med, 24, pp. 150-159
Shih, C.M., Hsu, W.H., Huang, W.T., Wang, J.J., Ho, S.T., Kao, A., Usefulness of chest single photon emission computed tomography with technetium-99m methoxyisobutylisonitrile to predict taxol based chemotherapy response in advanced non-small cell lung cancer (2003) Cancer Lett, 199, pp. 99-105
Kawata, K., Kanai, M., Sasada, T., Iwata, S., Yamamoto, N., Takabayashi, A., Usefulness of 99mTc-sestamibi scintigraphy in suggesting the therapeutic effect of chemotherapy against gastric cancer (2004) Clin Cancer Res, 10, pp. 3788-3793
Chang, C.S., Yang, S.S., Yeh, H.Z., Kao, C.H., Chen, G.H., Tc-99m MIBI liver imaging for hepatocellular carcinoma: Correlation with P-glycoprotein-multidrug-resistance gene expression (2004) Hepatogastroenterology, 51, pp. 211-214
Kostakoglu, L., Noninvasive detection of multidrug resistance in patients with hematological malignancies: Are we there yet? (2002) Clin Lymphoma, 2, pp. 242-248
Fonti, R., Del Vecchio, S., Zannetti, A., De Renzo, A., Catalano, L., Pace, L., Functional imaging of multidrug resistant phenotype by 99mTc-MIBI scan in patients with multiple myeloma (2004) Cancer Biother Radiopharm, 19, pp. 165-170
Ciarmiello, A., Del Vecchio, S., Silvestro, P., Potena, M.I., Carriero, M.V., Thomas, R., Tumor clearance of techrictium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer (1998) J Clin Oncol, 16, pp. 1677-1683
Sciuto, R., Pasqualoni, R., Bergomi, S., Petrilli, G., Vici, P., Belli, F., Prognostic value of (99m)Tc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy (2002) J Nucl Med, 43, pp. 745-751
Takamura, Y., Miyoshi, Y., Taguchi, T., Noguchi, S., Prediction of chemotherapeutic response by Technetium 99m--MIBI scintigraphy in breast carcinoma patients (2001) Cancer, 92, pp. 232-239
Mubashar, M., Harrington, K.J., Chaudhary, K.S., Lalani el, N., Stamp, G.W., Sinnett, D., 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer (2002) J Nucl Med, 43, pp. 519-525
Burak, Z., Moretti, J.L., Ersoy, O., Sanli, U., Kantar, M., Tamgac, F., 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression (2003) J Nucl Med, 44, pp. 1394-1401
Pace, L., Catalano, L., Del Vecchio, S., De Renzo, A., Fonti, R., Salvatore, B., Washout of [99mTc] sestamibi in predicting response to chemotherapy in patients with multiple myeloma. Q (2005) J Nucl Med Mol Imaging, 49, pp. 281-285
Pusztai, L., Wagner, P., Ibrahim, N., Rivera, E., Theriault, R., Booser, D., Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma (2005) Cancer, 104, pp. 682-691
Bates, S.E., Bakke, S., Kang, M., Robey, R.W., Zhai, S., Thambi, P., A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma (2004) Clin Cancer Res, 10, pp. 4724-4733
Chen, C.C., Meadows, B., Regis, J., Kalafsky, G., Fojo, T., Carrasquillo, J.A., Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi (1997) Clin Cancer Res, 3, pp. 545-552
Peck, R.A., Hewett, J., Harding, M.W., Wang, Y.M., Chaturvedi, P.R., Bhatnagar, A., Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin (2001) J Clin Oncol, 19, pp. 3130-3141
Agrawal, M., Abraham, J., Balis, F.M., Edgerly, M., Stein, W.D., Bates, S., Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576 (2003) Clin Cancer Res, 9, pp. 650-656
Wong, M., Evans, S., Rivory, L.P., Hoskins, J.M., Mann, G.J., Farlow, D., Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer (2005) Clin Pharmacol Ther, 77, pp. 33-42
Hendrikse, N.H., Kuipers, F., Meijer, C., Havinga, R., Bijleveld, C.M., van der Graaf, W.T., In vivo imaging of hepatobiliaxy transport function mediated by multidrug resistance associated protein and P-glycoprotein (2004) Cancer Chemother Pharmacol, 54, pp. 131-138
Menon, C., Fraker, D.L., Tumor oxygenation status as a prognostic marker (2005) Cancer Lett, 221, pp. 225-235
Krause, B.J., Beck, R., Souvatzoglou, M., Piert, M., PET and PET/CT studies of tumor tissue oxygenation. Q (2006) J Nucl Med Mol Imaging, 50, pp. 28-43
Eschmann, S.M., Paulsen, F., Reimold, M., Dittmann, H., Welz, S., Reischl, G., Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy (2005) J Nucl Med, 46, pp. 253-260
Lehtio, K., Fskola, O., Viljanen, T., Oikonen, V., Gronroos, T., Sillanmaki, L., Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer (2004) Int J Radiat Oncol Biol Phys, 59, pp. 971-982
Dehdashti, F., Grigsby, P.W., Mintun, M.A., Lewis, J.S., Siegel, B.A., Welch, M.J., Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: Relationship to therapeutic response: a preliminary report (2003) Int J Radiat Oncol Biol Phys, 55, pp. 1233-1238
Hicks, R.J., Rischin, D., Fisher, R., Binns, D., Scott, A.M., Peters, L.J., Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent (2005) Eur J Nucl Med Mol Imaging, 32, pp. 1384-1391
Hayes, D. F., Prognostic and predictive factors revisited (2005) Breast, 14, pp. 493-49
Chang, J. C., Wooten, E. C., Tsimelzon, A., Hilsenbeck, S. G., Gutierrez, M. C., Tham, Y. L., Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients (2005) J Clin Oncol, 23, pp. 1169-1177
Jeffrey, S. S., Lonning, P. E., Hillner, B. E., Genomics-based prognosis and therapeutic prediction in breast cancer (2005) J Natl Compr Canc Netw, 3, pp. 291-300
Robbins, R. J., Schlumberger, M. J., The evolving role of (131) I for the treatment of differentiated thyroid carcinoma (2005) J Nucl Med, 46 (SUPPL. 1), pp. 28S-37S
Reubi, J. C., Macke, H. R., Krenning, E. P., Candidates for peptide receptor radiotherapy today and in the future (2005) J Nucl Med, 46 (SUPPL. 1), pp. 67S-75S
Corsten, M. F., Hofstra, L., Narula, J., Reutelingsperger, C. P., Counting heads in the war against cancer: Defining the role of annexin A5 imaging in cancer treatment and surveillance (2006) Cancer Res, 66, pp. 1255-1260
Weber, W. A., Wieder, H., Monitoring chemotherapy and radiotherapy of solid tumors (2006) Eur J Nucl Med Mol Imaging, 33 (SUPPL. 13), pp. 27-37
Reilly, R. M., Kiarash, R., Sandhu, J., Lee, Y. W., Cameron, R. G., Hendler, A., A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer (2000) J Nucl Med, 41, pp. 903-911
Wen, X., Wu, Q. P., Ke, S., Ellis, L., Charnsangavej, C., Delpassand, A. S., Conjugation with (111) In-DTPA-poly (ethylene glycol) improves imaging of anti-EGF receptor antibody C225 (2001) J Nucl Med, 42, pp. 1530-1537
Perk, L. F., Visser, G. W., Vosjan, M. J., Stigter-van Walsum, M., Tijink, B. M., Leemans, C. R., (89) Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90) Y and (177) Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab (2005) J Nucl Med, 46, pp. 1898-1906
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., McGuire, W. L., Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene (1987) Science, 235, pp. 177-182
Zalutsky, M. R., Xu, F. J., Yu, Y., Foulon, C. F., Zhao, X. G., Slade, S. K., Radioiodinated antibody targeting of the HER-2/neu oncoprotein: Effects of labeling method on cellular processing and tissue distribution (1999) Nucl Med Biol, 26, pp. 781-790
Tsai, S. W., Sun, Y., William, L. E., Raubitschek, A. A., Wu, A. M., Shively, J. E., Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5 (2000) Bioconjug Chem, 11, pp. 327-334
Lub-de Hooge, M. N., Kosterink, J. G., Perik, P. J., Nijnuis, H., Tran, L., Bart, J., Preclinical characterisation of 111In-DTPA-trastuzumab (2004) Br J Pharmacol, 143, pp. 99-106
Perik, P. J., Lub-De Hooge, M. N., Gietema, J. A., van der Graaf, W. T., de Korte, M. A., Jonkman, S., Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer (2006) J Clin Oncol, 24, pp. 2276-2282
Robinson, M. K., Doss, M., Shaller, C., Narayanan, D., Marks, J. D., Adler, L. P., Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody (2005) Cancer Res, 65, pp. 1471-1478
Smith-Jones, P. M., Solit, D. B., Akhurst, T., Afroze, F., Rosen, N., Larson, S. M., Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors (2004) Nat Biotechnol, 22, pp. 701-706
Hay, R. V., Cao, B., Skinner, R. S., Su, Y., Zhao, P., Gustafson, M. F., Nuclear imaging of Met-expressing human and canine cancer xenografts with radiolabeled monoclonal antibodies (MetSeek) (2005) Clin Cancer Res, 11, pp. 7064s-77069. , s
Bonasera, T. A., Ortu, G., Rozen, Y., Krais, R., Freedman, N. M., Chisin, R., Potential (18) F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase (2001) Nucl Med Biol, 28, pp. 359-374
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib (2004) N Engl J Med, 350, pp. 2129-2139
Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy (2004) Science, 304, pp. 1497-1500
Johnson, B. E., Janne, P. A., Epidermal growth factor receptor mutations in patients with non-small cell lung cancer (2005) Cancer Res, 65, pp. 7525-7529
Veach, D. R., Namavari, M., Beresten, T., Balatoni, J., Minchenko, M., Djaballah, H., Synthesis and in vitro examination of [124I] -, [125I] - and [131I] -2- (4-iodophenylamino) pyrido [2, 3-d] pyrimidin-7-one radiolabeled Abl kinase inhibitors (2005) Nucl Med Biol, 32, pp. 313-321
Adams, G. P., Weiner, L. M., Monoclonal antibody therapy of cancer (2005) Nat Biotechnol, 23, pp. 1147-1157
Spies, S. M., Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevahn) (2004) Semin Nucl Med, 34, pp. 10-13
Conti, P. S., Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin): The role of the nuclear medicine physician (2004) Semin Nucl Med, 34, pp. 2-3
Conti, P. S., White, C., Pieslor, P., Molina, A., Aussie, J., Foster, P., The role of imaging with (111) In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: Results from a Zevalin Imaging Registry (2005) J Nucl Med, 46, pp. 1812-1818
DeNardo, G. L., Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs) (2005) Semin Nucl Med, 35, pp. 202-211
Wu, A. M., Senter, P. D., Arming antibodies: Prospects and challenges for immunoconjugates (2005) Nat Biotechnol, 23, pp. 1137-1146
Begent, R. H., Verhaar, M. J., Chester, K. A., Casey, J. L., Green, A. J., Napier, M., Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library (1996) Nat Med, 2, pp. 979-984
Larson, S. M., El-Shirbiny, A. M., Divgi, C. R., Sgouros, G., Finn, R. D., Tschmelitsch, J., Single chain antigen binding protein (sFv CC49): First human studies in colorectal carcinoma metastatic to liver (1997) Cancer, 80, pp. 2458-2468
Wong, J. Y., Chu, D. Z., Williams, L. E., Yamauchi, D. M., Ikle, N., Kwok, C. S., Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84. 66 minibody) in patients with colorectal cancer (2004) Clin Cancer Res, 10, pp. 5014-5021
Shields, A. F., Grierson, J. R., Dohmen, B. M., Machulla, H. J., Stayanoff, J. C., Lawhorn-Crews, J. M., Imaging proliferation in vivo with [F-18] FLT and positron emission tomography (1998) Nat Med, 4, pp. 1334-1336
Been, L. B., Suurmeijer, A. J., Cobben, D. C., Jager, P. L., Hoekstra, H. J., Elsinga, P. H., 18F] FLT-PET in oncology: Current status and opportunities (2004) Eur J Nucl Med Mol Imaging, 31, pp. 1659-1672
Buck, A. K., Schirrmeister, H., Hetzel, M., Von Der Heide, M., Halter, G., Glatting, G., 3-deoxy-3- [(18) F] fluorothynidine-positron emission tomography for noninvasive assessment of proliteration in pulmonary nodules (2002) Cancer Res, 62, pp. 3331-3334
44: 1426-31Muzi, M., Vesselle, H., Grierson, J. R., Mankoff, D. A., Schmidt, R. A., Peterson, L., Kinetic analysis of 3 -deoxy-3 -fluorothymidine PET studies: Validation studies in patients with lung cancer (2005) J Nucl Med, 46, pp. 274-282
Buck, A. K., Hetzel, M., Schirrmeister, H., Halter, G., Moller, P., Kratochwil, C., Clinical relevance of imaging proliferative activity in lung nodules (2005) Eur J Nucl Med Mol Imaging, 32, pp. 525-533
Yap, C. S., Czernin, J., Fishbein, M. C., Cameron, R. B., Schiepers, C., Phelps, M. E., Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography (2006) Chest, 129, pp. 393-401
van Westreenen, H. L., Cobben, D. C., Jager, P. L., van Dullemen, H. M., Wesseling, J., Elsinga, P. H., Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer (2005) J Nucl Med, 46, pp. 400-404
Francis, D. L., Visvikis, D., Costa, D. C., Arulampalam, T. H., Townsend, C., Ludira, S. K., Potential impact of [18F] 3 -deoxy-3 -fluorothymidine versus [18F] fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal. cancer (2003) Eur J Nucl Med Mol Imaging, 30, pp. 988-994
Jacobs, A. H., Thomas, A., Kracht, L. W., Li, H., Dittmar, C., Garhp, G., 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors (2005) J Nucl Med, 46, pp. 1948-1958
Choi, S. J., Kim, J. S., Kim, J. H., Oh, S. J., Lee, J. G., Kim, C. J., 18F] 3 -deoxy-3 -fluorothymidine PET for the diagnosis and grading of brain tumors (2005) Eur J Nucl Med Mol Imaging, 32, pp. 653-659
Kenny, L. M., Vigushin, D. M., Al-Nahhas, A., Osman, S., Luthra, S. K., Shousha, S., Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F] fluorothymidine-positron emission tomography imaging: Evaluation of analytical methods (2005) Cancer Res, 65, pp. 10104-10112
Yang, Y. J., Ryu, J. S., Kim, S. Y., Oh, S. J., Im, K. C., Lee, H., Use of 3 -deoxy-3 - [(18) F] fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors (2006) Eur J Nucl Med Mol Imaging, 33, pp. 412-419
Gottesman, M. M., Fojo, T., Bates, S. E., Multidrug resistance in cancer: Role of ATP-dependent transporters (2002) Nat Rev Cancer, 2, pp. 48-58
Leonard, G. D., Fojo, T., Bates, S. E., The role of ABC transporters in clinical practice (2003) Oncologist, 8, pp. 411-424
Trock, B. J., Leonessa, F., Clarke, R., Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance (1997) J Natl Cancer Inst, 89, pp. 917-931
Vecchio, S. D., Ciarmiello, A., Potena, M. I., Carriero, M. V., Mainolfi, C., Botti, G., In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients (1997) Eur J Nucl Med, 24, pp. 150-159
Shih, C. M., Hsu, W. H., Huang, W. T., Wang, J. J., Ho, S. T., Kao, A., Usefulness of chest single photon emission computed tomography with technetium-99m methoxyisobutylisonitrile to predict taxol based chemotherapy response in advanced non-small cell lung cancer (2003) Cancer Lett, 199, pp. 99-105
Chang, C. S., Yang, S. S., Yeh, H. Z., Kao, C. H., Chen, G. H., Tc-99m MIBI liver imaging for hepatocellular carcinoma: Correlation with P-glycoprotein-multidrug-resistance gene expression (2004) Hepatogastroenterology, 51, pp. 211-214
Bates, S. E., Bakke, S., Kang, M., Robey, R. W., Zhai, S., Thambi, P., A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma (2004) Clin Cancer Res, 10, pp. 4724-4733
Chen, C. C., Meadows, B., Regis, J., Kalafsky, G., Fojo, T., Carrasquillo, J. A., Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi (1997) Clin Cancer Res, 3, pp. 545-552
Peck, R. A., Hewett, J., Harding, M. W., Wang, Y. M., Chaturvedi, P. R., Bhatnagar, A., Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin (2001) J Clin Oncol, 19, pp. 3130-3141
Hendrikse, N. H., Kuipers, F., Meijer, C., Havinga, R., Bijleveld, C. M., van der Graaf, W. T., In vivo imaging of hepatobiliaxy transport function mediated by multidrug resistance associated protein and P-glycoprotein (2004) Cancer Chemother Pharmacol, 54, pp. 131-138
Krause, B. J., Beck, R., Souvatzoglou, M., Piert, M., PET and PET/CT studies of tumor tissue oxygenation. Q (2006) J Nucl Med Mol Imaging, 50, pp. 28-43
Eschmann, S. M., Paulsen, F., Reimold, M., Dittmann, H., Welz, S., Reischl, G., Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy (2005) J Nucl Med, 46, pp. 253-260
Hicks, R. J., Rischin, D., Fisher, R., Binns, D., Scott, A. M., Peters, L. J., Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent (2005) Eur J Nucl Med Mol Imaging, 32, pp. 1384-1391
Linden, H. M., Stekhova, S. A., Link, J. M., Gralow, J. R., Livingston, R. B., Ellis, G. K., Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment (2006) J Clin Oncol, 24, pp. 2793-2799
Nuclear imaging in cancer theranostics
The combination of a diagnostic test with a therapeutic entity is termed theranostics. The diagnostic test aims at identifying patients who will likely benefit from a specific therapeutic intervention, fail to respond or eventually manifest side effects to a given drug. The appropriate selection of patients for innovative therapies would promote an enrichment of patient population that can potentiate clinical trials and, eventually, accelerate the drug development process. For these reasons, many drug companies adopted a theranostic approach as a new and promising avenue for drug development. From an historical perspective, the concepts underlying the theranostic strategy are well known in nuclear medicine and constituted the basis of many nuclear imaging procedures currently used in clinical practice. Nevertheless the adoption of these concepts by regulatory authorities is a real progress and reflects the remarkable advances in the development of drugs against molecular targets. In this respect, the oncological field provides the strongest evidence of the clinical need to link diagnostics to therapeutics. Here, we review the contribution that non-invasive nuclear imaging may give to cancer theranostics and report prominent examples of nuclear imaging procedures that can be coupled to specific therapies. The main focus lies on imaging procedures that can identify patients who will benefit from molecularly targeted therapy or are going to fail to respond to standard treatment.
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(284 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote